How to Build a High-Value Biopharma Consulting Firm Through Commercial Excellence With Gregory Lief скачать в хорошем качестве

How to Build a High-Value Biopharma Consulting Firm Through Commercial Excellence With Gregory Lief

Description: Gregory Lief is the Founder & Managing Director of Asymmetry Group, where he advises innovative biopharma and life sciences companies as they transition from early-stage development to commercial-stage growth. With leadership experience at Biogen and Life Technologies, Greg brings deep expertise in launch excellence, commercial strategy, and capability building. In this episode, we unpack what it really takes to scale in a high-stakes, highly regulated industry. ********************************************************** Links: StreamYard (for guest): https://streamyard.com/wwm366f46a YouTube (for sharing):    • How to Build a High-Value Biopharma Consul...   Apply to be a guest: https://ghapodcast.com/application-to... ********************************************************** Gregory's Bio: Gregory Lief is the Founder & Managing Director of Asymmetry Group, a strategy and commercialization advisory firm serving innovative biopharmaceutical and life sciences companies. He previously led Global Commercial Excellence & Operations at Biogen, overseeing Strategic Insights & Analytics, Forecasting, Sales Force Effectiveness, Marketing Excellence, and Integrated Product Planning. Greg has managed operating budgets up to $50M and built international teams across the U.S. and Europe. He holds an MBA from Northwestern University’s Kellogg School of Management and a BA in Biology from Dartmouth College. ********************************************************** Show Notes: Gregory Lief operates at the intersection of strategy and execution in biopharma. After leading Global Commercial Excellence & Operations at Biogen, reporting to the Chief Commercial Officer, he founded Asymmetry Group to help emerging healthcare companies make the leap from science-driven organizations to commercially disciplined businesses. His work spans corporate strategy, launch planning, marketing and sales operations, forecasting, and capability development. What makes Greg’s perspective different is that he’s built these systems inside large global organizations and now translates that experience into advisory support for high-growth life sciences firms. For consulting firm owners, this conversation is about leverage: how to move from insight to infrastructure, how to design governance that scales, and why asymmetric thinking, not benchmarking to the average, drives durable advantage. ********************************************************** Proposed Interview Structure: 1. Greg, you’ve led strategy and commercial operations inside major biotech organizations. What originally pulled you into consulting and commercial strategy within healthcare? 2. What specific problem are you solving today with Asymmetry Group when a biopharma company calls you, and why is that transition from development-stage to commercial-stage so difficult? 3. Who are your ideal clients right now? Are you working primarily with venture-backed biotech, mid-size pharma, or more established players, and who is usually the decision maker? 4. In such a specialized industry, how do clients typically find you? What has worked best to attract the right kind of engagements? Current Acquisition Channels: Referral, Content Sub Question: What’s your perspective on podcasting as a marketing tool in the biopharma or life sciences consulting space? 5. Given the long, complex buying cycles in biotech, multiple stakeholders, scientific scrutiny, budget approvals, how do you typically move from first conversation to signed engagement? 6. How do you retain clients over the long term, and what do you do deliberately to ensure they keep coming back and see you as a trusted partner rather than a one-off advisor? 7. Where do you find yourself most stuck right now as a consulting firm founder in the biopharma space (if at all)? 8. Looking ahead, where do you see the biggest opportunity for commercialization strategy and launch excellence in biopharma over the next few years?